About Medpace Holdings, Inc.
https://www.medpace.comMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
CEO
August James Troendle
Compensation Summary
(Year 2019)
ETFs Holding This Stock
IJH.AX
Weight:0.41%
Shares:710.73K
XMC.TO
Weight:0.41%
Shares:710.73K
VTS.AX
Weight:0.02%
Shares:706.32K
Summary
Showing Top 3 of 271
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Barclays
Underweight
Truist Securities
Hold
Mizuho
Outperform
TD Cowen
Sell
Jefferies
Hold
Rothschild & Co
Neutral
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:2.58M
Value:$1.58B
BLACKROCK, INC.
Shares:2.36M
Value:$1.44B
VANGUARD GROUP INC
Shares:2.28M
Value:$1.39B
Summary
Showing Top 3 of 778
About Medpace Holdings, Inc.
https://www.medpace.comMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $659.9M ▲ | $55.13M ▲ | $111.14M ▲ | 16.84% ▲ | $3.95 ▲ | $149.88M ▲ |
| Q2-2025 | $603.31M ▲ | $53.68M ▼ | $90.26M ▼ | 14.96% ▼ | $3.16 ▼ | $117.61M ▼ |
| Q1-2025 | $558.57M ▲ | $64.83M ▲ | $114.59M ▼ | 20.52% ▼ | $3.77 ▼ | $120.45M ▼ |
| Q4-2024 | $536.59M ▲ | $52.94M ▼ | $117.02M ▲ | 21.81% ▲ | $3.78 ▲ | $132.88M ▲ |
| Q3-2024 | $533.32M | $56.73M | $96.43M | 18.08% | $3.11 | $119.79M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $285.35M ▲ | $1.75B ▲ | $1.46B ▲ | $293.64M ▲ |
| Q2-2025 | $46.33M ▼ | $1.57B ▼ | $1.4B ▲ | $172.35M ▼ |
| Q1-2025 | $441.44M ▼ | $1.9B ▼ | $1.3B ▲ | $593.61M ▼ |
| Q4-2024 | $669.44M ▲ | $2.1B ▲ | $1.28B ▲ | $825.54M ▼ |
| Q3-2024 | $656.9M | $2.08B | $1.2B | $881.44M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $111.14M ▲ | $246.21M ▲ | $-10.66M ▼ | $3.41M ▲ | $239.02M ▲ | $262.32M ▲ |
| Q2-2025 | $90.26M ▼ | $148.53M ▲ | $-6.02M ▲ | $-540.56M ▼ | $-395.11M ▼ | $142.41M ▲ |
| Q1-2025 | $114.59M ▼ | $125.84M ▼ | $-9.99M ▼ | $-345.97M ▼ | $-228M ▼ | $115.84M ▼ |
| Q4-2024 | $117.02M ▲ | $190.67M ▲ | $-7.56M ▲ | $-168.61M ▼ | $12.54M ▼ | $183.02M ▲ |
| Q3-2024 | $96.43M | $149.07M | $-10.49M | $6.27M | $146.01M | $138.54M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Antiviral And Anti Infective | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $40.00M ▲ |
 Cardiology | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ |
 Central Nervous System | $50.00M ▲ | $50.00M ▲ | $60.00M ▲ | $70.00M ▲ |
 Metabolic | $120.00M ▲ | $150.00M ▲ | $150.00M ▲ | $200.00M ▲ |
 Oncology | $170.00M ▲ | $170.00M ▲ | $190.00M ▲ | $190.00M ▲ |
 Other | $100.00M ▲ | $100.00M ▲ | $120.00M ▲ | $110.00M ▼ |
CEO
August James Troendle
Compensation Summary
(Year 2019)
ETFs Holding This Stock
IJH.AX
Weight:0.41%
Shares:710.73K
XMC.TO
Weight:0.41%
Shares:710.73K
VTS.AX
Weight:0.02%
Shares:706.32K
Summary
Showing Top 3 of 271
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Barclays
Underweight
Truist Securities
Hold
Mizuho
Outperform
TD Cowen
Sell
Jefferies
Hold
Rothschild & Co
Neutral
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:2.58M
Value:$1.58B
BLACKROCK, INC.
Shares:2.36M
Value:$1.44B
VANGUARD GROUP INC
Shares:2.28M
Value:$1.39B
Summary
Showing Top 3 of 778